Products Most ACE inhibitors are commercially available in the form of tablets and film-coated tablets. The first agent from this group to be approved was captopril, in many countries in 1980. ACE inhibitors are often combined with the thiazide diuretic hydrochlorothiazide (HCT) fix. Structure and properties ACE inhibitors are peptidomimetics derived from peptides found in … ACE Inhibitors List, Effects, Side Effects
Products The first agent in the GLP-1 receptor agonist group to be approved was exenatide (Byetta) in the United States in 2005 and in many countries and the EU in 2006. In the meantime, several other drugs have been registered (see below). These drugs are also known as incretin mimetics. They are commercially available as … GLP-1 Receptor Agonists
Symptoms The possible acute symptoms of type 2 diabetes include: Thirst (polydipsia) and hunger (polyphagia). Increased urination (polyuria). Visual disturbances Weight loss Fatigue, exhaustion, declining performance. Poor wound healing, infectious diseases. Skin lesions, itching Acute complications: Hyperacidity (ketoacidosis), hyperosmolar hyperglycemic syndrome. Untreated diabetes is far from harmless and can lead in the longer term to … Diabetes Mellitus Type 2: Causes and Treatment
Products Exenatide is commercially available as an injectable (Byetta, Bydureon). It was approved in the United States in 2005 as the first agent in the GLP-1 receptor agonist group (Byetta). In many countries, the drug was registered a year later. The long-acting Bydureon Pen was approved in many countries in 2012, with additional approval as … Exenatide
Products Saxagliptin is commercially available in the form of film-coated tablets (Onglyza). It was approved in many countries after sitagliptin (Januvia) and vildagliptin (Galvus) as the 3rd active ingredient from the gliptins group in February 2010. Since 2012, two additional combination products with metformin have been registered (Duoglyze, Kombiglyze XR). Kombiglyze XR entered the market … Saxagliptin
Products Lixisenatide was approved as a subcutaneous solution for injection in the EU in 2012, in the United States in 2016, and in many countries in 2017 (Lyxumia). Lixisenatide is also combined with insulin glargine; see iGlarLixi (Suliqua). Structure and properties Lixisenatide is a peptide and GLP1 analog of 44 amino acids that, like exenatide, … Lixisenatide
Products Liraglutide was approved in many countries in 2009 as a solution for injection in a prefilled pen (Victoza). In 2014, a fixed-dose combination with insulin degludec was released (Xultophy); see IDegLira. In 2016, Saxenda was registered for the treatment of overweight and obesity. Its related successor, semaglutide, unlike liraglutide, only needs to be injected … Liraglutide
Products Gliptins are commercially available in the form of film-coated tablets. Sitagliptin (Januvia) was the first representative to be approved in the United States in 2006. Today, various active ingredients and combination products are commercially available (see below). They are also called dipeptidyl peptidase-4 inhibitors. Structure and properties Some gliptins have a proline-like structure because … Gliptine
Active ingredients Insulins substitute for endogenous insulin: Human insulin Insulin analogues Biguanides reduce hepatic glucose formation: Metformin (Glucophage, generic). Sulfonylureas promote insulin secretion from beta cells: Glibenclamide (Daonil, generic). Glibornuride (Glutril, off label). Gliclazide (Diamicron, generic). Glimepiride (Amaryl, generics) Glinides promote insulin secretion from beta cells: Repaglinide (NovoNorm, generic). Nateglinide (Starlix) Glitazones decrease peripheral insulin … Antidiabetics
Products Dulaglutide was approved as a solution for injection in many countries in 2015 (Trulicity). Structure and properties Dulaglutide (ATC A10BJ05) is a fusion protein consisting of two identical chains linked by disulfide bridges. The chains contain: The GLP-1 analog (sequence segment 7-37), which is 90% the same as the natural GLP-1 segment. It has … Dulaglutide
Products Albiglutide was approved in many countries, in the EU, and in the United States in 2014 in the form of an injectable (Eperzan). Structure and properties Albiglutide is a GLP-1 dimer (fragment of 30 amino acids, 7-36) fused to the human protein albumin. The amino acid alanine at position 8 has been replaced by … Albiglutide
Products Vildagliptin is commercially available in tablet form as a monopreparation (Galvus) and in fixed combination with metformin (Galvumet). It has been approved in the EU since 2007 and in many countries since 2008. Generic versions were registered in 2020. Structure and properties Vildagliptin (C17H25N3O2, Mr = 303.40 g/mol) is a hydroxy-adamantane, a carbonitrile and … Vildagliptin
